Greenleaf Trust Abb Vie Inc. Transaction History

Greenleaf Trust

$11.2 Billion
Q3 2024

A detailed history of Greenleaf Trust transactions in Abb Vie Inc. stock. As of the latest transaction made, Greenleaf Trust holds 104,541 shares of ABBV stock, worth $18.8 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

104,541

Previous 100,530 3.99%

Holding current value

$18.8 Million

Previous $17.2 Million 19.73%

% of portfolio

0.18%

Previous 0.16%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	BUY	$163.84 - $199.33 $657,162 - $799,512	4,011 Added 3.99%	104,541 $20.6 Million
Q2 2024 Jul 22, 2024	BUY	$154.79 - $180.76 $589,130 - $687,972	3,806 Added 3.93%	100,530 $17.2 Million
Q1 2024 Apr 29, 2024	BUY	$159.82 - $182.1 $150,230 - $171,174	940 Added 0.98%	96,724 $17.6 Million
Q4 2023 Jan 31, 2024	BUY	$137.6 - $154.97 $1.39 Million - $1.56 Million	10,073 Added 11.75%	95,784 $14.8 Million
Q3 2023 Nov 09, 2023	BUY	$133.59 - $154.65 $152,826 - $176,919	1,144 Added 1.35%	85,711 $12.8 Million
Q2 2023 Aug 09, 2023	SELL	$132.51 - $164.9 $109,983 - $136,867	-830 Reduced 0.97%	84,567 $11.4 Million
Q1 2023 May 11, 2023	BUY	$144.61 - $166.54 $915,959 - $1.05 Million	6,334 Added 8.01%	85,397 $13.6 Million
Q4 2022 Jan 25, 2023	SELL	$138.31 - $165.87 $5.6 Million - $6.72 Million	-40,496 Reduced 33.87%	79,063 $12.8 Million
Q3 2022 Nov 10, 2022	BUY	$134.21 - $153.93 $6.83 Million - $7.84 Million	50,904 Added 74.14%	119,559 $16 Million
Q2 2022 Aug 12, 2022	BUY	$137.62 - $174.96 $1.87 Million - $2.38 Million	13,604 Added 24.71%	68,655 $10.5 Million
Q1 2022 Apr 27, 2022	SELL	$131.98 - $163.75 $524,488 - $650,742	-3,974 Reduced 6.73%	55,051 $8.92 Million
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $927,443 - $1.17 Million	8,633 Added 17.13%	59,025 $7.99 Million
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $112,464 - $127,664	-1,057 Reduced 2.05%	50,392 $5.44 Million
Q2 2021 Aug 10, 2021	BUY	$105.21 - $117.21 $426,626 - $475,286	4,055 Added 8.56%	51,449 $5.8 Million
Q1 2021 Apr 30, 2021	BUY	$102.3 - $112.62 $203,474 - $224,001	1,989 Added 4.38%	47,394 $5.13 Million
Q4 2020 Feb 08, 2021	BUY	$80.49 - $108.67 $314,554 - $424,682	3,908 Added 9.42%	45,405 $4.87 Million
Q3 2020 Oct 30, 2020	BUY	$85.91 - $100.83 $252,489 - $296,339	2,939 Added 7.62%	41,497 $3.64 Million
Q2 2020 Aug 12, 2020	BUY	$73.37 - $98.18 $364,355 - $487,561	4,966 Added 14.78%	38,558 $3.79 Million
Q1 2020 Apr 29, 2020	SELL	$64.5 - $97.79 $10,642 - $16,135	-165 Reduced 0.49%	33,592 $2.56 Million
Q4 2019 Feb 11, 2020	BUY	$72.13 - $90.25 $222,521 - $278,421	3,085 Added 10.06%	33,757 $2.99 Million
Q3 2019 Nov 08, 2019	SELL	$62.98 - $75.72 $346,830 - $416,990	-5,507 Reduced 15.22%	30,672 $2.32 Million
Q2 2019 Jul 24, 2019	BUY	$65.7 - $83.98 $177,915 - $227,417	2,708 Added 8.09%	36,179 $2.63 Million
Q1 2019 May 08, 2019	SELL	$77.14 - $90.79 $413,393 - $486,543	-5,359 Reduced 13.8%	33,471 $2.7 Million
Q4 2018 Feb 07, 2019	BUY	$77.85 - $96.01 $336,623 - $415,147	4,324 Added 12.53%	38,830 $3.58 Million
Q3 2018 Oct 29, 2018	SELL	$88.91 - $98.84 $238,278 - $264,891	-2,680 Reduced 7.21%	34,506 $3.26 Million
Q2 2018 Aug 07, 2018	BUY	$89.78 - $106.23 $356,426 - $421,733	3,970 Added 11.95%	37,186 $3.45 Million
Q1 2018 Apr 30, 2018	SELL	$92.01 - $123.21 $252,291 - $337,841	-2,742 Reduced 7.63%	33,216 $3.14 Million
Q4 2017 Feb 08, 2018	SELL	$89.56 - $98.21 $132,727 - $145,547	-1,482 Reduced 3.96%	35,958 $3.48 Million
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $2.62 Million - $3.34 Million	37,440	37,440 $3.33 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenleaf Trust, based on Form 13F filings with the SEC.

News

Stay updated on Greenleaf Trust with notifications on news.

Account